Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.64 |
| ▸ | CCR2 | P41597 | 4/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prozapine SCHEMBL25765 | 1.00 | ALDH1A1 (0.66) | ALDH1A1KCNA3CCR2CYP2D6OPRL1 | |
| Fenpiprane SCHEMBL11585426 | 0.98 | ALDH1A1 (0.64) | ALDH1A1KCNA3CCR2CYP2D6OPRL1 | |
| Prozapine SCHEMBL365642 | 0.98 | ALDH1A1 (0.64) | ALDH1A1KCNA3CCR2CYP2D6OPRL1 | |
| SCHEMBL67164 | 0.89 | SIGMAR1 (0.66) | ALDH1A1SIGMAR1CACNA1B | |
| Hydrochloric Acid SCHEMBL29267226 | 0.88 | CYP3A4 (0.66) | ALDH1A1KCNA3CCR2CYP2D6OPRL1 | |
| Hydrochloric Acid SCHEMBL30517299 | 0.88 | CYP3A4 (0.66) | ALDH1A1KCNA3CCR2CYP2D6OPRL1 | |
| Diisopromine SCHEMBL28142824 | 0.84 | ALDH1A1 (0.51) | ALDH1A1KCNA3CCR2CYP2D6OPRL1 | |
| SCHEMBL5757757 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KCNA3CCR2CYP2D6SIGMAR1 | |
| SCHEMBL7547846 | 0.83 | HTR1A (0.61) | SLC6A3 | |
| SCHEMBL6009479 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KCNA3CCR2CYP2D6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065205-B2 | Immediate/delayed drug delivery | DRUG DELIVERY INTERNATIONAL LIMITED (GB) | 2021-07-20 | — | — | US | claimed |
| WO-2019155389-A1 | AN AQUEOUS MUCOADHESIVE AND BIOADHESIVE COMPOSITION FOR THE TREATMENT | TARGET ONCOLOGY INC. (US) | 2019-08-15 | — | — | WO | claimed |
| US-20190125679-A1 | IMMEDIATE/DELAYED DRUG DELIVERY | UNIVERSITY OF STRATHCLYDE (GB) | 2019-05-02 | — | — | US | claimed |
| EP-3373943-A1 | CONTROL OF CELLULAR REDOX LEVELS | Mckenna, Elizabeth (US) | 2018-09-19 | — | — | EP | claimed |
| CN-108430482-A | Control of cellular redox levels | 伊丽莎白·麦克纳 | 2018-08-21 | — | — | CN | claimed |
| EP-2956450-B1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | UNIV MUENCHEN TECH (DE) | 2018-07-25 | — | — | EP | claimed |
| EP-2542226-B1 | DELAYED PROLONGED DRUG DELIVERY | UNIV STRATHCLYDE (GB) | 2017-11-22 | — | — | EP | claimed |
| WO-2017083470-A1 | CONTROL OF CELLULAR REDOX LEVELS | MCKENNA ELIZABETH (US) | 2017-05-18 | — | — | WO | claimed |
| US-9474719-B2 | Pulsatile drug release | UNIVERSITY OF STRATHCLYDE (GB) | 2016-10-25 | — | — | US | claimed |
| US-9283192-B2 | Delayed prolonged drug delivery | UNIVERSITY OF STRATHCLYDE (GB) | 2016-03-15 | — | — | US | claimed |
| CN-1738599-A | Mucoadhesive erodible drug delivery device for controlled drug administration with other active compounds | ACCESS PHARMA INC (US) | 2006-02-22 | — | — | CN | claimed |
| EP-1418889-A2 | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMINISTRATION OF PHARMACEUTICALS AND OTHER ACTIVE COMPOUNDS | Access Pharmaceuticals, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20030138490-A1 | Synthesis and uses of polymer gel nanoparticle networks | HU ZHIBING (US) | 2003-07-24 | — | — | US | claimed |
| US-6585997-B2 | Comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non- adhesive backing layer that controls residence time of the device | ACCESS PHARMACEUTICALS, INC. | 2003-07-01 | — | — | US | claimed |
| WO-2003022910-A1 | SYNTHESIS AND USES OF POLYMER GEL NANOPARTICLE NETWORKS | ACCESS PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| US-20030044446-A1 | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMN. OF PHARMACEUTICALS & OTHER ACTI | 2003-03-06 | — | — | US | claimed |
| WO-2003015748-A2 | MUCOADHESIVE ERODIBLE DRUG DELIVERY DEVICE FOR CONTROLLED ADMINISTRATION OF PHARMACEUTICALS AND OTHER ACTIVE COMPOUNDS | ACCESS PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138490-A1 | Synthesis and uses of polymer gel nanoparticle networks | NCLN, PNN, TAGLN2 | ALDH1A1 2310/4885KCNA3 3459/4885CCR2 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.